Transgene announced today that recent animal efficacy studies done on the oral delivery of insulin using Transgene's patented oral delivery technology, TrabiOral, have shown spectacular results. Sustained optimal glycemic levels were demonstrated for approximately 10 hours following the oral dosage.

Read More

Transgene has signed a Memorandum of Understanding with Armour Therapeutics of Canada to develop a novel delivery method for Armour's prostrate cancer molecule. Transgene has also signed a term sheet with New York based investment advisory firm HealthPro BioVentures. HealthPro will be exploring strategic opportunities for Transgene's pipeline.

Read More

Transgene Biotek today announced the commencement of commercial manufacturing operations of DHA, an Omega-3 fatty acid used as a nutraceutical product in health foods and supplements. GOED (Global Organization for EPA and DHA) currently values the Omega-3 market at US $18.6 billion (Rs. 90,000 Cr), and yet demand still outstrips supply.

Read More

We plan to utilise the proceeds to continue funding the development of our pipeline, construct an FDA compliant facility for the manufacture of API’s, expand growth via acquisitions, and to support the filing of a large number of new patents.

Transgene’s pipeline of projects consists of a host of ‘orphan’ drugs including molecules to treat Multiple myeloma and Multiple sclerosis, six anti-cancer molecules and a therapeutic vaccine to combat AIDS. Several of these molecules have reached the last stages of preclinical development and we now intend to begin filing INDA’s before the end of this year, after which we will likely begin to look towards partnering for one or two of these molecules.

Inorganic growth will become a key strategy for us going forward, something we believe will rapidly boost revenues, increase physical infrastructure, raise technology development expertise and skills, and also bring with it a list of key blue-chip clients who may in turn become ideal candidates for our molecule partnering program. Our acquisition search will extend into Europe and America which in turn will also give us a much awaited footprint into the Western markets.

One of Transgene’s strengths has been the maintenance of our Intellectual Property portfolio. The new capital raised will also be used towards the legal and regulatory expenses in filing new worldwide patents on our latest technology developments – something we believe will become the cornerstone of our value tomorrow.

Chinny Rao, Executive Director said “This GDR listing heralds a new era for Transgene. The point at which we are with our pipeline today, coupled with the Board’s new strategy to expand our presence abroad not only from the GDR listing but from what is now a strong desire to expand inorganically should set the tone for the future. We’re already in talks to begin that partnering search, and we’re already in the midst of a search for acquisition targets – so to me the future is bright, very bright in fact.

Transgene declared today that one of its monoclonal antibodies (mAb), which was originally developed for Colon Cancer, has demonstrated remarkable efficacy against two additional cancers, namely Multiple Myeloma and Non-Hodgkin's Lymphoma. So far, there is no other known monoclonal antibody drug in the world that has demonstrated a similar therapeutic effect against all three cancers.

Read More

Transgene has added a drug for Colon Cancer that uses its Monoclonal Antibody technology platform to its Oncology pipeline. Recent in-vitro studies have clearly established its specificity, and have proved that it is an excellent cancer target drug.

Read More

Two new patents have been filed by Transgene for their proprietary autoimmune technology platform. The first patent, for a therapeutic AIDS vaccine, was filed after it crossed a significant milestone in proving its effectiveness. The second patent, for a drug against the serious neurological disorder Multiple Sclerosis, also employs Transgene's proprietary autoimmune technology platform.

Read More

Transgene has filed 2 patents for its Liver and Breast Cancer drug technologies based on its proprietary RNAi platform. Both patents follow excellent results in their respective animal studies. Liver cancer is the 3rd most common cause of cancer mortality, and breast cancer is the most common cancer in women. The company is expecting to file more patents on some of its other technologies shortly.

Read More

A new drug for treating Breast Cancer, developed using Transgene's proprietary RNAi technology platform, has demonstrated exciting results in its latest animal studies. This drug is specifically designed not only to treat primary Breast Cancer but also to fight against potential metastatic tumours. Worldwide, Breast Cancer is the most common cancer in women, representing 16% of all female cancers, and causes well over 500,000 deaths annually.

Read More

A novel drug for Liver Cancer developed by Transgene Biotek's scientists has demonstrated excellent efficacy in the latest animal studies, which corroborates earlier data gathered from in-vitro studies. Transgene has employed its RNAi platform, which utilizes a novel gene silencing technology, to develop this drug, which has demonstrated remarkable regression of the tumours in tests. Liver Cancer is the fifth most common cancer in the world, and the third most common cause of cancer mortality.

Read More

Transgene Biotek has crossed a significant milestone in demonstrating the efficacy of a therapeutic AIDS vaccine developed by its scientists. This vaccine prevents the progression of AIDS in HIV infected persons, and almost reverses the AIDS process by enabling reactivation of the body's natural immunity, which otherwise gets depleted and often results in death. The AIDS vaccine is the first product to come out of a novel platform that Transgene has built for drugs against auto-immune diseases. Other drugs currently under development on this platform target Rheumatoid Arthritis and Multiple Sclerosis, and the platform can be extended against other autoimmune diseases such as Crohn's Disease etc.

Read More

The second announcement of Dr Reddy's is a tie-up with Indian biotechnology company Transgene Biotek to manufacture and market Orlistat, an obesity management drug. The market size for obesity management drugs accounts for $2 billion worldwide with pancreatic lipase inhibitors such as Orlistat contributing to about half of this.

Read More

Transgene Biotek (TBL) has entered into a Licensing and Technology Transfer Agreement with Dr. Reddy's Labs (DRL) for the outlicensing of a technology for the manufacture of Orlistat, which was developed exclusively by TBL. This unique technology will be licensed by TBL and manufactured and marketed by Dr. Reddy's globally. The agreement should lead to substantial revenues being generated for TBL and DRL for several years to come, and to a many fold increase in TBL's bottomline. The market for Orlistat is estimated to be around US $500 million per year.

Read More